Oramed Pharmaceuticals (NASDAQ:ORMP) Announces Earnings Results

Oramed Pharmaceuticals (NASDAQ:ORMP) posted its quarterly earnings data on Thursday. The biotechnology company reported $0.43 EPS for the quarter, hitting analysts’ consensus estimates of $0.43, FiscalAI reports.

Oramed Pharmaceuticals Price Performance

Shares of ORMP stock traded down $0.10 on Thursday, reaching $4.03. 111,223 shares of the stock were exchanged, compared to its average volume of 119,392. Oramed Pharmaceuticals has a one year low of $2.25 and a one year high of $5.47. The stock has a market cap of $167.65 million, a PE ratio of 0.98 and a beta of 1.31. The stock has a 50 day moving average price of $4.38 and a 200 day moving average price of $4.05.

Insider Activity

In related news, COO Joshua Hexter sold 30,000 shares of Oramed Pharmaceuticals stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $4.51, for a total value of $135,300.00. Following the completion of the sale, the chief operating officer directly owned 1,328,130 shares in the company, valued at $5,989,866.30. This trade represents a 2.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Avraham Gabay sold 20,000 shares of Oramed Pharmaceuticals stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $4.51, for a total transaction of $90,200.00. Following the sale, the chief financial officer directly owned 861,076 shares of the company’s stock, valued at $3,883,452.76. This represents a 2.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 20.77% of the stock is owned by company insiders.

Analyst Ratings Changes

Several brokerages recently issued reports on ORMP. Wall Street Zen downgraded shares of Oramed Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, November 7th. Weiss Ratings raised shares of Oramed Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Friday, October 23rd. One equities research analyst has rated the stock with a Buy rating. According to MarketBeat.com, Oramed Pharmaceuticals has an average rating of “Buy”.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company developing oral drug-delivery technologies. Its platform is designed to protect protein-based medicines as they pass through the digestive system and support their absorption, with the aim of delivering medicines by mouth that have traditionally been given by injection. The company’s research has focused on oral treatments for metabolic conditions, including ORMD-0801, an oral insulin candidate, and an oral GLP-1 candidate. These products are investigational; Oramed does not market them as approved treatments.